Related Experiment Videos
The potential of pneumococcal conjugate vaccines for children
Cynthia G Whitney1, Larry K Pickering
1Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. Cwhitney@cdc.gov
Insights
Pneumococcal conjugate vaccines show promise in reducing infant disease. While effective, they alter serotype carriage, raising questions about long-term impact and the need for global access.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health
Background:
- Pneumococcal conjugate vaccines offer a significant advancement over earlier formulations for infants and young children.
- The first seven-valent conjugate vaccine was licensed in 2000 and is now a routine immunization in the US, with high demand exceeding supply.
Purpose of the Study:
- To evaluate the efficacy of pneumococcal conjugate vaccines against invasive pneumococcal disease, otitis media, and pneumonia.
- To assess the impact of conjugate vaccines on nasopharyngeal carriage of *Streptococcus pneumoniae* serotypes.
Main Methods:
- Clinical trials were conducted to determine vaccine efficacy.
- Carriage studies were performed to analyze changes in serotype prevalence post-vaccination.
Main Results:
- Conjugate vaccines demonstrated high efficacy against invasive pneumococcal disease and moderate efficacy against otitis media and pneumonia.
- Vaccine-type carriage was reduced, but an increase in non-vaccine serotype carriage was observed.
Conclusions:
- Further monitoring of disease burden is crucial to understand the long-term effects of widespread conjugate vaccine use.
- Ensuring availability of pneumococcal vaccines for children in developing countries is a global health priority.
Abstract:
In contrast to earlier pneumococcal vaccines, conjugate vaccines hold promise for reducing pneumococcal morbidity and mortality in infants and young children. The first commercially available conjugate vaccine formulation, which targets seven serotypes, was licensed in the US and other countries in 2000; this vaccine is now part of routine infant immunization in the US. Demand has been high and greater than vaccine supply. Clinical trials indicate that conjugate vaccines are highly efficacious against invasive pneumococcal disease and modestly efficacious against otitis media and pneumonia. In carriage studies conjugate vaccines reduced vaccine-type carriage but led to an increase in carriage of other serotypes. Remaining questions include whether less frequent transmission of vaccine serotypes will mean less disease in unvaccinated children and adults or if nonvaccine serotypes will begin to cause more disease. Monitoring disease burden after widespread use in the US is critical for understanding the effects of the vaccine. In addition making pneumococcal vaccines available for children in developing countries should be a high priority.